Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifaximin

FDA-approved product (tablet, oral), marketed as Rifaximin, Xifaxan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifaximin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Hepatic failure
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA11; WHO ATC D06AX11; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifaximin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA93.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli70.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifaximin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifaximin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rifaximin Versus Lactulose in Renal Failure

    NCT00748904 · start 2008-06

    Registered record
    Registry ID
    NCT00748904
    Conditions
    Liver Cirrhosis; Renal Failure
    Interventions
    Rifaximin; Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-06
    Completion
    2009-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Renal Failure
    InterventionRifaximin; Lactulose
    PhasePhase 4
    Registry statusWithdrawn

  • Gulf War Digestive Health Study

    NCT00680836 · start 2007-10

    Registered record
    Registry ID
    NCT00680836
    Conditions
    Irritable Bowel Syndrome; Small Intestinal Bacterial Overgrowth
    Interventions
    Placebo; Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-10
    Completion
    2013-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome; Small Intestinal Bacterial Overgrowth
    InterventionPlacebo; Rifaximin
    PhaseNot applicable
    Registry statusCompleted

  • Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

    NCT00528073 · start 2007-09

    Registered record
    Registry ID
    NCT00528073
    Conditions
    Crohn's Disease
    Interventions
    Rifaximin-EIR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-10
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionRifaximin-EIR
    PhasePhase 2
    Registry statusCompleted

  • Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

    NCT01137955 · start 2006-10

    Registered record
    Registry ID
    NCT01137955
    Conditions
    Celiac Disease
    Interventions
    Rifaximin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-10
    Completion
    2008-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCeliac Disease
    InterventionRifaximin; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

    NCT00098384 · start 2003-06

    Registered record
    Registry ID
    NCT00098384
    Conditions
    Diarrhea
    Interventions
    rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2003-09
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea
    Interventionrifaximin
    PhasePhase 2
    Registry statusCompleted